The first two oral antivirals, molnupiravir and nirmatrelvir–ritonavir, are now becoming
available in many countries. These medicines will be indicated to treat mild-to-moderate …

Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …

The brutal logic that has divided the world into vaccine haves and havenots is now being
repeated as gamechanging COVID-19 drugs like Pfizer's oral antiviral Paxlovid (nirmatrelvir …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management - The
Lancet Skip to Main Content Advertisement The Lancet Journal Submit Article Log in Register …

On Dec 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use
authorisation for Pfizer's COVID-19 antiviral, Paxlovid. Trial results released by the …

Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …

The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …